Medtronic gains FDA OK for heart resynchronization device

05/7/2013 | Bloomberg Businessweek

The FDA has granted Medtronic approval to market its Viva system, an implantable device used to treat heart failure by resynchronizing the beating of a patient's heart. Patients who received the device saw 21% reduced hospitalizations during the first year of implantation compared with those using traditional systems, a company official said.

View Full Article in:

Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN